Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: The study C randomized controlled trial

JAMA

Volumn 305, Issue 14, 2011, Pages 1415-1423

  Lienhardt, Christian ^a   Cook, Sharlette V ^a   Burgos, Marcos ^b   Yorke Edwards, Victoria ^c   Rigouts, Leen ^d   Anyo, Gladys ^d   Kim, Sang Jae ^e   Jindani, Amina ^f   Enarson, Don A ^a   Nunn, Andrew J ^c  

^a INTERNATIONAL UNION AGAINST TUBERCULOSIS AND LUNG DISEASE   (France)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

^d INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^e International Tuberculosis Research Center   (South Korea)

^f ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID; ISONIAZID PLUS RIFAMPICIN; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LIVER DISEASE; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGICAL EXAMINATION; MULTICENTER STUDY; OPEN STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATIC DISEASE; SKIN DISEASE; SPUTUM ANALYSIS; TREATMENT RESPONSE;

EID: 79953853899     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.436     Document Type: Article

References (27)

1. Raviglione MC. The Global Plan to Stop TB, 2006-2015. Int J Tuberc Lung Dis. 2006;10(3): 238-239.
2. Zignol M, Hosseini MS, Wright A, et al. Global incidence of multidrug-resistant tuberculosis. J Infect Dis. 2006;194(4):479-485. (Pubitemid 44162659)
3. International Union Against Tuberculosis and Lung Disease. Antituberculosis regimens of chemotherapy: recommendations from the Committee on Treatment of the International Union Against Tuberculosis and Lung Disease. Bull Int Union Tuberc Lung Dis. 1988;63(2):60-64.
4. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ. 2001;79(1):61-68. (Pubitemid 32154097)
5. Ellard GA, Ellard DR, Allen BW, et al. The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis. Am Rev Respir Dis. 1986;133(6): 1076-1080. (Pubitemid 16090016)
6. Geiter LJ, O'Brien RJ, Combs DL, Snider DE Jr. United States Public Health Service Tuberculosis Therapy Trial 21: preliminary results of an evaluation of a combination tablet of isoniazid, rifampin and pyrazinamide. Tubercle. 1987;68(2)(suppl):41-46. (Pubitemid 17128232)
7. Acocella G, Nonis A, Gialdroni-Grassi G, Grassi C. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy, I: single-dose study. Am Rev Respir Dis. 1988;138(4):882-885.
8. Singapore Tuberculosis Service/British Medical Research Council. Assessment of a daily combined preparation of isoniazid, rifampin, and pyrazinamide in a controlled trial of three 6-month regimens for smear-positive pulmonary tuberculosis. Am Rev Respir Dis. 1991;143(4, pt 1):707-712.
9. Hong Kong Chest Service/British Medical Research Council. Acceptability, compliance, and adverse reactions when isoniazid, rifampin, and pyrazinamide are given as a combined formulation or separately during three-times-weekly antituberculosis chemotherapy. Am Rev Respir Dis. 1989;140 (6):1618-1622.
10. Kudoh S, Kudoh T. A simple technique for culturing tubercle bacilli. Bull World Health Organ. 1974; 51(1):71-82.
11. Supply P, Allix C, Lesjean S, et al. Proposal for standardization of optimized mycobacterial interspersed repetitive unit-variable-number tandem repeat typing of Mycobacterium tuberculosis. J Clin Microbiol. 2006;44(12):4498-4510. (Pubitemid 44937085)
12. Jindani A, Nunn AJ, Enarson DA. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet. 2004;364(9441): 1244-1251. (Pubitemid 39311345)
13. Machin D, Campbell MJ. Statistical Tables for the Design of Clinical Trials. Oxford, UK: Blackwell Scientific Publications; 1987.
14. Stata Statistical Software Release 10. College Station, TX: StataCorp; 2007.
15. Bartacek A, Schütt D, Panosch B, Borek M; Rimstar 4-FDC Study Group. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis. 2009;13(6):760-766.
16. Gravendeel JM, Asapa AS, Becx-Bleumink M, Vrakking HA. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis (Edinb). 2003;83(1-3):183-186. (Pubitemid 36683570)
17. Su WJ, Perng RP. Fixed-dose combination chemotherapy (Rifater/Rifinah) for active pulmonary tuberculosis in Taiwan: a two-year follow-up. Int J Tuberc Lung Dis. 2002;6(11):1029-1032.
18. Briefing information for the June 3, 2009, meeting of the Anti-InfectiveDrugs Advisory Committee. US Food and Drug Administration Web site. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ Anti-InfectiveDrugsAdvisoryCommittee/ucm161856.htm. Accessed September 3, 2010.
19. Concept paper on preparation of an addendum to the guideline on development of antibacterial agents to specifically address the clinical development of new agents to treat tuberculosis (EMEA/CHMP/EWP /122355/2007). European Medicines Agency Website. http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003396.pdf. 2007. Accessed March 2, 2011.
20. Guideline on the choice of the non-inferiority margin (EMEA/CPMP/EWP/2158/99). European Medicines Agency Web site. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003636.pdf. July 2005. Accessed March 2, 2011.
21. Nunn AJ, Phillips PP, Gillespie SH. Design issues in pivotal drug trials for drug sensitive tuberculosis (TB). Tuberculosis (Edinb). 2008;88(suppl 1):S85-S92.
22. Piaggio G, Elbourne DR, Altman DG, Pocock SJ, Evans SJ; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement. JAMA. 2006; 295(10):1152-1160. (Pubitemid 43352345)
23. Forget EJ, Menzies D. Adverse reactions to firstline antituberculosis drugs. Expert OpinDrug Saf. 2006; 5(2):231-249. (Pubitemid 43379622)
24. Global Drug Facility. Stop TB Partnership Web site. http://www.stoptb. org/gdf/drugsupply/quality-sourcing-process.asp. Accessed September 3, 2010.
25. Treatment of tuberculosis: guidelines. 4th ed. World Health Organization Web site. http://www.who.int/tb/publications/tb-treatmentguidelines/en/index. html. 2009. Accessed September 3, 2010.
26. Lin Y. Progress and challenges in addressing the fixed-dose combination (FDC) bottleneck in TB control: summary of selected data. Presented at: Pacific Health Summit; Seattle, WA; June 18, 2009.
27. Lienhardt C, Vernon A, Raviglione MC. New drugs and new regimens for the treatment of tuberculosis: review of the drug development pipeline and implications for national programmes. Curr Opin Pulm Med. 2010;16(3):186-193.